Muscular Atrophy, Spinal
Conditions
Brief summary
This multicenter, randomized, double-blind, 12-week, placebo-controlled multiple dose study will investigate the safety and tolerability of RO6885247 in adult and pediatric patients with spinal muscular atrophy (SMA).
Interventions
DRUGRO6885247
oral solution
DRUGplacebo
oral solution
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
No minimum to 55 Years
Healthy volunteers
No
Inclusion criteria
* Males and females, aged 2 to 55 years inclusive or below 7 months inclusive * Confirmed diagnosis of 5q-autosomal recessive SMA (Types 1 to 3), for patients aged 7 months or below clinical symptoms attributable to type 1 SMA and 2 SMN2 copies * Able and willing to provide informed consent and to comply with the study protocol. Alternatively, a legally authorized representative must be able to consent for the patient and assent must be given by the subject wherever possible. * Female patients of childbearing potential and male patients with a female partner of childbearing potential must agree with the required contraceptive methods as defined per protocol. * For patients aged 7 months or below, Gestational age of 37 to 42 weeks and not considered small for gestational age at birth
Exclusion criteria
* Concomitant or previous participation in any investigational drug or device study within 90 days prior to screening * Concomitant or previous participation in a SMN2-targeting antisense oligonucleotide study within 12 months prior to screening * Concomitant or previous participation at any time in a gene therapy study * For patients aged 2-55 years, hospitalization for pulmonary event within the last 2 months or planned at the time of screening * Surgery for scoliosis in the last 6 months from screening or planned within 6 months from screening * Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease * Clinically relevant ECG abnormalities at screening or baseline; personal or family history (first degree relatives) of congenital long QT syndrome * Clinically significant abnormalities in laboratory test results at screening * Any concomitant disease or condition that could interfere with the conduct of the study, or pose an unacceptable risk to the subject in this study * Use of prohibited medications as per protocol within 90 days prior to randomization. Patients who are on inhaled corticosteroids, administered either through a nebulizer or an inhaler, are allowed. * Recently initiated treatment (within \<6 months prior to randomization) with oral salbutamol or another beta2-adrenergic agonist taken orally is not allowed. Patients who have been on oral salbutamol (or another beta2-adrenergic agonist) for at least 6 months before randomization are allowed. Use of inhaled beta2-adrenergic agonists is allowed. * For patients aged 7 months or below, patients requiring invasive ventilation or tracheostomy, presence of non-SMA related morbidities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety: Incidence of adverse events (AEs) | Up to 20 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics: RO6885247 exposure, area under the concentration-time curve (AUC-tau, over the 24-hour dosing interval) | Up to 12 weeks |
| Pharmacodynamics: SMN protein levels in blood | Up to 20 weeks |
| Pharmacokinetics: RO6885247 plasma concentrations | Up to 16 weeks |
| Effect of RO6885247 on Electrical Impedance Myography | Up to 20 weeks |
| Pharmacodynamics: In vivo splicing modification of SMN2 mRNA in blood | Up to 20 weeks |
| Effect of RO6885247 on muscle electrophysiology, as assessed by Compound Muscle Action Potential (CMAP) | Up to 20 weeks |
Countries
Canada, France, Italy, Netherlands, Sweden, Switzerland, Turkey (Türkiye), United Kingdom, United States
Outcome results
None listed